上市捷报丨沙利文祝贺诺思格（北京）医药科技股份有限公司成功登陆创业板(301333)

Northgate (Beijing) Pharmaceutical Technology Co., Ltd. (Stock Code:301333) on2022year8month2Successfully logged into the ChiNext on the same day. The company has a complete clinical trial industry chain.CRO companyThe company provides a full range of clinical drug R&D services. Frost & SullivanFrost & Sullivan,Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan') hereby warmly congratulates the company on its successful listing.

Northpharm (Beijing) Pharmaceutical Technology Co., Ltd. (hereinafter referred to as 'Northpharm') was established on2022year8month2The company was successfully listed on the stock market, with the number of shares issued being1,50010,000 shares, issue price per share78.88yuan.

Northedge is a company with a complete clinical trial industry chain.CRO firmThe company can provide comprehensive clinical drug R&D services. It has a full-chain and all-domain service capability covering all stages of clinical trials, as well as rich resources of clinical trial institutions and clients. The main business of Nosight covers all stages of clinical trials, including clinical trial operation services, on-site clinical trial management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, clinical pharmacology services, etc., and can provide clinicalCRO companyFull-process service. After more than a decade of accumulation, Novogene has established good long-term cooperative relationships with researchers in various therapeutic fields and can quickly and efficiently assist sponsors in advancing clinical trials of their products. Novogene has served nearly500A customer,1,800The remaining clinical trial projects provide outsourced clinical trial services that meet domestic and international standards, establishing a good reputation in both domestic and international markets. We have maintained long-term and stable cooperative relationships with many high-quality pharmaceutical enterprise clients, including Novogene.

Frost & Sullivan has long been focusing on the global and Chinese biopharmaceutical industries, publishing a large number of research reports that are widely cited in the prospectuses of leading companies listed on the ChiNext, helping clients accelerate their growth.

Analysis of the Chinese Pharmaceutical Market

With the introduction of a series of supportive government policies such as 'Opinions on Deepening the Reform of the Review and Approval System to Encourage Innovation in Drugs and Medical Devices', the regulatory system and environment of China's pharmaceutical market have changed. These policies have accelerated drug review and approval processes, not only shortening the clinical trials and approval time for new drugs, allowing them to be launched as soon as possible, but also speeding up the review and approval of drugs urgently needed in clinical practice, encouraging new drug research and development. At the same time, the 'Opinions' encourage the promotion of generic drug production and accelerate the quality and efficacy consistency evaluation of generic drugs. With the support of China's policies and the continuous development of the pharmaceutical industry, it is expected that China's pharmaceutical market will continue to grow in the future.2018year15,334RMB 10 billion grew to2023year21,326100 billion RMB, with an annual compound growth rate of6.8%.

China's pharmaceutical market size2014 - 2023E

Data source: Analysis by Frost & Sullivan

Analysis of China's Pharmaceutical R&D Expenditure

The pharmaceutical industry in China is continuously developing from low-end imitation to research and development innovation, resulting in a continuous increase in pharmaceutical R&D investment.The market is long and growing at a rate far higher than the global average. At the same time, multinational pharmaceutical companies have increased their drug exports to China in order to explore the Chinese market, and have established R&D centers in China, creating a huge demand for clinical research on imported drugs.2014The R & D investment in pharmaceuticals in China in93billion dollars2018Year-on-year growth to174billions, with an average annual compound growth rate of about16.9%since2018Year-end2023In [year], China's R&D investment in pharmaceuticals is expected to be23.1%The average annual compound growth rate increased to493billion dollars.

China's pharmaceutical R&D expenditure and details2014 - 2023E

Data source: Analysis by Frost & Sullivan

Analysis of the China Pharmaceutical R&D Outsourcing Service Market

CRO companyProvides solutions for the drug development phase, includingDMPKSafety toxicology, bioanalysis, clinical trial monitoring,SMOServices such as data management and statistical analysis. Compared with developed countries like Europe and AmericaCRO companymarkets, emerging market countries such as chinaCRO companyBusiness growth has been more rapid. On one hand, emerging markets such as China have seen a continuous release of medical demand driven by factors like aging and urbanization. The pharmaceutical market has expanded rapidly, along with increased R&D investment, which has led to a rapid growth in outsourcing R&D services for the pharmaceutical industry. On the other hand, multinational pharmaceutical companies are gradually shifting their R&D operations to emerging markets such as China due to factors such as abundant talent resources and lower labor costs in these markets.2014Preclinical and clinical trials in China inCRO companyMarket scale is only18billion dollars, to2018Preclinical and clinical trials in China inCRO firmThe market has reached47billions, with an average annual compound growth rate of about28.0%.

Compared with developed countries, our countryCRO firmThe industry is still in its infancy, with enormous development potential. In the next few years, China's preclinical and clinicalCRO firmThe market will also remain29.4%The annual compound growth rate, up to2023Annual achievement172billion dollars.

Preclinical and clinical in ChinaCRO firmService market scale2014 - 2023E

Data source: Analysis by Frost & Sullivan

Analysis of the China Clinical Outsourcing Service Market

domesticCRO firmThe market started relatively late but has grown rapidly. By2018Year, Phase Clinical in ChinaCRO firmMarket scale reaches32billion dollars2014 - 2018The annual compound growth rate for the year reached31.3%With the continuous tightening of clinical research regulatory requirements and rising costs,CRO firmWith its professionalism and familiarity with industry policies and processes, it has gradually become a preferred cooperation option for pharmaceutical companies during the drug clinical research phase. Compared to the global market, Chinese pharmaceutical companies' choicesCRO firmThe proportion of services is still below global levels, and there is room for improvement in penetration rates.2023Chinese clinical phase inCRO companyThe market scale will reach133Billion US dollars, with a compound annual growth rate far higher than the global level during the same period.

Chinese clinical phaseCRO firmMarket scale2014 - 2023E

Data source: Analysis by Frost & Sullivan

Frost & Sullivan integrates globally.61years of consulting experience,24Frost & Sullivan is dedicated to serving the booming Chinese market with a global perspective, helping clients accelerate their business growth and achieve benchmark positions in industry growth, innovation, and leadership. The Greater Health Industry is one of the core areas of focus for Frost & Sullivan's research. Recently20For many years, the Frost & Sullivan team has provided financing and financial advisory services to hundreds of outstanding domestic and international biopharmaceutical, medical device, healthcare services, and internet healthcare companies.IPO listingIndustry consulting, strategic consulting, management consulting, and other services. Successful listings include: Zhiyun Health (9955.HK), MeinGene6667.HK),Prenetics（NASDAQ: PRE), Yunkang Group2325.HK), Ruike Biotechnology2179.HK), Leopu Biology2157.HK), Clear Medical1406.HK), Baisinkan2185.HK), Yonghe Medical (2279.HK), Kailaiying6821.HK), Beihai Kangcheng1228.HK), Gusheng Hall2273.HK), Eagle-Pen Technology2251.HK), Clover Biotechnology2197.HK), minimally invasive robots2252.HK), and Yuhuan Cayman2256.HK), Kunbo Medical (2216.HK), Xianruida6669.HK), Kangsheng Global9960.HK), Med66 (2192.HK), Tengsheng Bo medicine2137.HK), Conoco (2162.HK), Chaogju Eye Hospital2219.HK), Guichuangtong Bridge2190.HK), and Huang Medicine0013.HK), Keji Pharmaceutical2171.HK), Zhaoke Eye Hospital6622.HK), Nature MedicineUPC.NASDAQ), SinoBiologics (6600.HK), Zhaoyan New Drugs6127.HK), Novo Nordisk Health (6606.HK), Tianyan PharmaceuticalADAG.NASDAQ), Beikang Medical (2170.HK), Jianbimiao Miao Miao2161.HK), Minimally Invasive Cardiac Angioplasty (2160.HK), Ruili Medical Beauty2135.HK), Jiake Pharmaceutical1167.HK), and Bopan Medicine2142.HK), JD Health6618.HK), Deqi Medicine6996.HK), Rongchang Biology9995.HK), WuXi AppTec Genomics (2126.HK), Sinobiopharmaceuticals2096.HK), Yunding Xinyao1952.HK), Harvest Biotech6998.HK), ZaiDi Pharma9688.HK), Ocumivir1477.HK), Yongtai Biology6978.HK), Hype Pharma9989.HK), Kechuang Pharmaceutical9939.HK), Peijia Medical (9996.HK), Kangfang Biology9926.HK), Novartis HealthCare (9969.HK), Celestial BeingsIMAB.NASDAQ), Kanglonghua Cheng3759.HK), China Antibody3681.HK), Dongyao Pharmaceutical1875.HK), Yasheng Medicine6855.HK), Fosun Pharma (2696.HK), Hansoh Pharmaceutical3692.HK), Mabotech2181.HK), Founder Holdings1521.HK), Viva Biology1873.HK), CStone Pharmaceuticals2616.HK), Junshi Biology1877.HK), WuXi AppTec (2359.HK), Innovent Biologics1801.HK), Hualing Medicine2552.HK), BeiGene (6160.HK), Gelifarmaceuticals1672.HK), WuXi AppTec Biologics2269.HK), China Resources Medicine3320.HK), Yakult Biopharmaceuticals2633.HK), and Huang China MedicineHCM.NASDAQ), Biotechnology1548.HK),BBILife Sciences1035.HK) and so on. In terms of the number of submissions, Frost & Sullivan's healthcare team in Hong Kong is involved inIPO listingMaintain an absolute leading position,2018till2021Year after year, it has always ranked first in market share.

since2019year7Since the listing of the first batch of companies on the Sci-tech Innovation Board, Frost & Sullivan reports have also been widely referenced in the prospectuses of leading Sci-tech Innovation Board-listed companies, including: Yifang Biotechnology (688382.SH), Jicui YAKANG688046.SH), Haiscot Biopharmaceuticals688302.SH), Rongchang Biology688331.SH), Rendu Biology688193.SH), Capital Pharmaceutical Holdings (688197.SH), and Yuanbiotech (688238.SH), YASIN Security688225.SH), Xidiwei688173.SH), MyWay Biotechnology688062.SH), Yarong Medicine688176.SH), BeiGene (688235.SH), Jiahemeikang688246.SH), DiZhe Medicine688192.SH), Novozymes688105.SH), Chengda Biology688739.SH), Gecko Micro688728.SH), Huaxi Biology688363.SH), Junshi Biology688180.SH), Zhejiang Genomics & Therapeutics Co., Ltd.688266.SH), Bai'ao Tai688177.SH), SinoCell (688520.SH) and others are considered one of the most powerful, professional, and influential industry research institutions in the sector. We aim to work with enterprises to understand industry trends, seize development opportunities, jointly promote innovation and upgrading of China's big health industry, and build a healthy future.